Skip to main content

Table 3 MIC50s, MIC90s, and ranges of MICs of CAZ-AVI and ATM-AVI for 76 S. maltophilia isolates from clinical specimensa

From: Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro

Drug resistance phenotype (s) b
(no. of isolates)
CAZ CAZ + AVI CAZ-AVI MIC50 reduction (fold) ATM ATM + AVI ATM-AVI MIC50
reduction (fold)
MIC50 MIC90 range MIC50 MIC90 range MIC50 MIC90 range MIC50 MIC90 range
Total(76) 8 64 0.03–64 2 64 0.016–64 4 64 64 1–1024 2 8 0.06–64 32
MH-NSc or LVX-NS
or SXT-NS (60)
16 64 0.03–64 4 16 0.016–64 4 64 64 1–1024 2 8 0.06–64 32
MH-Sd and LEV-S
and SXT-S (16)
4 8 1–16 2 2 0.25–8 2 64 64 64 2 2 0.5–64 32
MDR (2) NAe NA > = 64 NA NA 16- > 64 NA NA NA 64 NA NA 2–8 NA
  1. aMICs are expressed in μg/mL
  2. bCAZ ceftazidime, ATM aztreonam, AVI avibactam, MDR multidrug resistant. Multidrug-resistant isolates were defined as isolates demonstrating resistance to at least one antimicrobial agent from three or more different classes
  3. cNS not susceptible, dS susceptible, eNA not applicable. MIC50s and MIC90s are not presented for groups of fewer than 6 isolates